Serena Desideri

3.5k total citations · 2 hit papers
69 papers, 2.7k citations indexed

About

Serena Desideri is a scholar working on Genetics, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Serena Desideri has authored 69 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Genetics, 29 papers in Oncology and 18 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Serena Desideri's work include Glioma Diagnosis and Treatment (55 papers), Brain Metastases and Treatment (14 papers) and PARP inhibition in cancer therapy (10 papers). Serena Desideri is often cited by papers focused on Glioma Diagnosis and Treatment (55 papers), Brain Metastases and Treatment (14 papers) and PARP inhibition in cancer therapy (10 papers). Serena Desideri collaborates with scholars based in United States, Italy and Australia. Serena Desideri's co-authors include Stuart A. Grossman, Xiaobu Ye, Steven Piantadosi, Glenn J. Lesser, Joy Fisher, Myrna R. Rosenfeld, Burt Nabors, Tom Mikkelsen, Tracy T. Batchelor and Andrew E. Sloan and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Neurology.

In The Last Decade

Serena Desideri

65 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide

2011 413 citations Stuart A. Grossman, Xiaobu Ye et al. Clinical Cancer Research profile →
A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme

2014 409 citations Myrna R. Rosenfeld, Xiaobu Ye et al. Autophagy profile →

Peers

Countries citing papers authored by Serena Desideri

Since Specialization

Citations

This map shows the geographic impact of Serena Desideri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Serena Desideri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Serena Desideri more than expected).

Fields of papers citing papers by Serena Desideri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Serena Desideri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Serena Desideri. The network helps show where Serena Desideri may publish in the future.

Co-authorship network of co-authors of Serena Desideri

This figure shows the co-authorship network connecting the top 25 collaborators of Serena Desideri. A scholar is included among the top collaborators of Serena Desideri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Serena Desideri. Serena Desideri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas 2025 ·Neuro-Oncology ·David Schiff, Xiaobu Ye, Jing Li, Benjamin M. Ellingson, Patrick Y Wen, Tobias Walbert, Jian Campian, Burt Nabors, (unknown), Arati Desai, Antonio Omuro, Serena Desideri, (unknown), Stuart A. Grossman, Ranjit S. Bindra	0
2	Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma 2024 ·Clinical Cancer Research ·Karisa C. Schreck, Roy E. Strowd, Burt Nabors, Benjamin M. Ellingson, Michael Chang, Sze Kiat Tan, Zied Abdullaev, Rust Turakulov, Kenneth Aldape, (unknown), Serena Desideri, Joy Fisher, (unknown), (unknown), Michelle A. Rudek, Chetan Bettegowda, Stuart A. Grossman, Xiaobu Ye	7
3	Phase I and pharmacodynamic study of arsenic trioxide plus radiotherapy in patients with newly diagnosed glioblastoma 2024 ·Neuro-Oncology Advances ·Samuel Ryu, Xiaobu Ye, Jeffrey J. Olson, Tom Mikkelsen, Lev Bangiyev, Glenn J. Lesser, Tracy T. Batchelor, Burt Nabors, Serena Desideri, Tobias Walbert, Stuart A. Grossman	4
4	Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma 2023 ·Journal of Neuro-Oncology ·Roy E. Strowd, Benjamin M. Ellingson, Catalina Raymond, Jingwen Yao, Patrick Y. Wen, Manmeet S. Ahluwalia, Anna F. Piotrowski, Arati Desai, Jennifer Clarke, Frank S. Lieberman, Serena Desideri, Burt Nabors, Xiaobu Ye, Stuart A. Grossman	17
5	ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449 2022 ·Journal of Neuro-Oncology ·Andrew E. Sloan, Charles Nock, Xiaobu Ye, (unknown), Susan M. Chang, Glenn J. Lesser, Andrew D. Norden, Timothy F. Cloughesy, Jeffrey J. Olson, Amber Kerstetter-Fogle, Jeremy N. Rich, Joy Fisher, Serena Desideri, Naoko Takebe, William C. Timmer, Stuart A. Grossman, Michael D. Prados	9
6	Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma 2018 ·Clinical Cancer Research ·Jaishri O. Blakeley, Stuart A. Grossman, S. Andrew, Tom Mikkelsen, Myrna R. Rosenfeld, Manmeet S. Ahluwalia, Burt Nabors, April F. Eichler, (unknown), Serena Desideri, Xiaobu Ye	18
7	Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas 2017 ·Neuro-Oncology ·Matthias Holdhoff, Xiaobu Ye, Jeffrey G. Supko, Burt Nabors, Arati Desai, Tobias Walbert, Glenn J. Lesser, William L. Read, Frank S. Lieberman, Martin A. Lodge, Jeffrey P. Leal, Joy Fisher, Serena Desideri, Stuart A. Grossman, Richard L. Wahl, David Schiff	43
8	Repeatability of ¹⁸F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma 2016 ·Journal of Nuclear Medicine ·Martin A. Lodge, Matthias Holdhoff, Jeffrey P. Leal, Asim K. Bag, Burt Nabors, Akiva Mintz, Glenn J. Lesser, David A. Mankoff, Arati Desai, James M. Mountz, Frank S. Lieberman, Joy Fisher, Serena Desideri, Xiaobu Ye, Stuart A. Grossman, David Schiff, Richard L. Wahl	23
9	Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma 2016 ·Journal of Neuro-Oncology ·Edward Pan, Jeffrey G. Supko, Thomas Kaley, Nicholas Butowski, Timothy F. Cloughesy, Jinkyu Jung, Serena Desideri, Stuart A. Grossman, Xiaobu Ye, Deric M. Park	41
10	A prospective multicenter study of venous thromboembolism in patients with newly-diagnosed high-grade glioma: hazard rate and risk factors 2015 ·Journal of Neuro-Oncology ·Michael B. Streiff, Xiaobu Ye, Thomas S. Kickler, Serena Desideri, Jayesh Jani, Joy Fisher, Stuart A. Grossman	66
11	A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme breakdown → 2014 ·Autophagy ·Myrna R. Rosenfeld, Xiaobu Ye, Jeffrey G. Supko, Serena Desideri, Stuart A. Grossman, Steven Brem, Tom Mikkelson, Daniel Wang, Yunyoung C Chang, (unknown), Quentin McAfee, Joy Fisher, Andrea B. Troxel, Shengfu Piao, Daniel F. Heitjan, (unknown), Laura Pontiggia, Peter J. O’Dwyer, Lisa E. Davis, Ravi K. Amaravadi	409
12	Phase I study of terameprocol in patients with recurrent high-grade glioma 2012 ·Neuro-Oncology ·Stuart A. Grossman, (unknown), D. Peereboom, Myrna R. Rosenfeld, Tom Mikkelsen, Jeffrey G. Supko, Serena Desideri	53
13	Correlation of treatment effects on progression-free survival at 6 months (PFS-6) and overall survival (OS) in patients with newly diagnosed glioblastoma (GBM). 2011 ·Journal of Clinical Oncology ·(unknown), Stuart A. Grossman, Serena Desideri, Steven Piantadosi	1
14	A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas 2010 ·Journal of Neuro-Oncology ·David M. Peereboom, Jeffrey G. Supko, Kathryn A. Carson, Tracy T. Batchelor, Surasak Phuphanich, Glenn J. Lesser, Tom Mikkelson, Joy Fisher, Serena Desideri, (unknown), Stuart A. Grossman	18
15	A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma 2010 ·Neuro-Oncology ·Myrna R. Rosenfeld, M. C. Chamberlain, Stuart A. Grossman, David M. Peereboom, Glenn J. Lesser, Tracy T. Batchelor, Serena Desideri, Amy M. Salazar, X. Ye	89
16	Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma 2010 ·Journal of Neuro-Oncology ·Surasak Phuphanich, Jeffrey G. Supko, Kathryn A. Carson, Stuart A. Grossman, Burt Nabors, Tom Mikkelsen, Glenn J. Lesser, Steve Rosenfeld, Serena Desideri, Jeffrey J. Olson	58
17	Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial 2009 ·Journal of Clinical Oncology ·Stuart A. Grossman, Xiaobu Ye, Marc C. Chamberlain, Tom Mikkelsen, Tracy T. Batchelor, Serena Desideri, Steven Piantadosi, Joy Fisher, Howard A. Fine	131
18	Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma 2008 ·Neuro-Oncology ·Surasak Phuphanich, Kathryn A. Carson, Stuart A. Grossman, Glenn J. Lesser, Jeffrey J. Olson, Tom Mikkelsen, Serena Desideri, Joy Fisher	18
19	Effect of Regain of Body Weight on Regional Body Fat Distribution: Comparison Between Pre‐ and Postmenopausal Obese Women 1996 ·Obesity Research ·Mauro Zamboni, F Armellini, E Turcato, Rocco Micciolo, Serena Desideri, I A Bergamo-Andreis, Ottavio Bosello	14
20	Coated Oral 5-Aminosalicylic Acid (Claversal) Is Equivalent to Sulfasalazine for Remission Maintenance in Ulcerative Colitis 1995 ·Journal of Clinical Gastroenterology ·Sandro Ardizzone, Marco Petrillo, P. Molteni, Serena Desideri, G. Bianchi Porro	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact